They may prescribe stronger long-term medication or biologics to help improve your symptoms and quality of life. Managing the symptoms of eosinophilic asthma could help reduce your risk for lung ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

Eosinophilic asthma is a severe form of asthma caused by excess amounts of white blood cells that cause inflammation in the respiratory system. It’s rare and difficult to treat, and requires ...

GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's ...

Uncontrolled eosinophilic inflammation is a risk factor for asthma exacerbations, airway remodeling, and decline in lung function. Previous proof of concept trials have shown that an anti-interleukin ...

Areteia Therapeutics, Inc. ("Areteia") today announced that effective immediately its Board of Directors has appointed Donald J. Hayden, Jr. as Chair of the Board and Ian F. Smith as Chair of the ...

Department of Medicine, University of Pittsburgh Asthma Institute at UPMC/UPSOM, 3459 Fifth Avenue, NW 628 Montefiore, Pittsburgh, PA 15213, USA; wenzelse{at}upmc.edu Background Eosinophilic ...

Department of Respiratory and Sleep Medicine, John Hunter Hospital, Locked Bag 1, Hunter Region Mail Centre, NSW 2310 Australia; mdpgg{at}mail.newcastle.edu.au Airway inflammation with eosinophils is ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License ...